Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
08:00am, Tuesday, 06'th Apr 2021
WILMINGTON, Mass. & MONTREAL--(BUSINESS WIRE)---- $CRL #Biopharma--Charles River and Valence Discovery announce strategic partnership to provide clients access to AI-enabled drug design.
Charles River Laboratories Completes the Acquisition of Cognate BioServices
04:15pm, Monday, 29'th Mar 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River Laboratories completes the acquisition of Cognate BioServices.
Charles River Laboratories Announces Closing of Senior Notes Offering
04:30pm, Tuesday, 23'rd Mar 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announced that it has closed its previously announced offering of $1 billion of senior notes
ETF Strategies to Hedge Against Inflation
05:26pm, Thursday, 11'th Mar 2021
Here are some ways to protect your portfolio from rising inflation.
Charles River Laboratories Prices $1 Billion of Senior Notes
08:00am, Tuesday, 09'th Mar 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories prices $1 billion of senior notes
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
09:15am, Monday, 08'th Mar 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories announces planned offering of $1 billion of senior notes
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
08:00am, Thursday, 25'th Feb 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Today, Charles River announced a partnership with Kibur Medical to offer exclusive access to its IMD for in vivo preclincal oncology studies.
Charles River - Powering Along
04:12am, Sunday, 21'st Feb 2021
Charles Rivers has done well during the pandemic as the pain was short-lived. While it is not a prime beneficiary of Covid-19, the company continues to help its clients progress their pipelines.
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q4 2020 Results - Earnings Call Transcript
03:25pm, Wednesday, 17'th Feb 2021
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q4 2020 Results - Earnings Call Transcript
Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates
09:06am, Wednesday, 17'th Feb 2021
Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
07:08am, Wednesday, 17'th Feb 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Fourth-quarter and Full-year 2020 Results and Provides 2021 Guidance
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
07:06am, Wednesday, 17'th Feb 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to acquire Cognate Bioservices
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
01:12pm, Wednesday, 10'th Feb 2021
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Algernon Pharmaceuticals inks deal with Charles River Laboratories for preclinical work on DMT for stroke
09:33am, Monday, 08'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, said pre-clinical studies on the psychedelic compound DMT to treat stroke will be carried out at the Charl
Why Charles River (CRL) Could Beat Earnings Estimates Again
12:47pm, Friday, 29'th Jan 2021
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
